None of the proposed mechanisms of Alzheimer's disease (AD) fully explains the distribution patterns of the neuropathological changes at the cellular and regional levels, and their …
D Švob Štrac, N Pivac, D Mück-Šeler - Translational neuroscience, 2016 - degruyter.com
Symptoms of cognitive dysfunction like memory loss, poor concentration, impaired learning and executive functions are characteristic features of both schizophrenia and Alzheimer's …
Alzheimer's disease (AD) is one of the major neurodegenerative diseases that deteriorates cognitive functions and primarily affects associated brain regions involved in learning and …
N Family, EL Maillet, LTJ Williams, E Krediet… - …, 2020 - Springer
Abstract Research has shown that psychedelics, such as lysergic acid diethylamide (LSD), have profound anti-inflammatory properties mediated by 5-HT 2A receptor signaling …
Primary prevention trials have shifted their focus to the earliest stages of Alzheimer's disease (AD). Autopsy data indicates that the neuromodulatory subcortical systems'(NSS) nuclei are …
Positron emission tomography (PET) is a well-established imaging modality. Measurement of regional cerebral glucose metabolism (rCMRglc) using PET and [18F]-2-fluoro-2-deoxy-d …
EP Bauer - Behavioural brain research, 2015 - Elsevier
This review describes the latest developments in our understanding of how the serotonergic system modulates Pavlovian fear conditioning, fear expression and fear extinction. These …
HN Saeger, DE Olson - Journal of neurochemistry, 2022 - Wiley Online Library
Psychedelics are increasingly being recognized for their potential to treat a wide range of brain disorders including depression, post‐traumatic stress disorder (PTSD), and substance …
Neuropsychiatric symptoms of Alzheimer's disease (NPS-AD) are highly prevalent and lead to poor medical and functional outcomes. In spite of the burdensome nature of NPS-AD, we …